Acceleron Pharma (XLRN)
Acceleron Pharma
NASDAQ:XLRN (11/19/2021, 7:33:57 PM)
After market: 179.92 +1.17 (+0.65%)178.75
-0.93 (-0.52%)
Company Profile
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 312 full-time employees. The company went IPO on 2013-09-18. The firm is focused on its research, development, and commercialization efforts in pulmonary and hematologic diseases. Its research is focused on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta) protein superfamily. The firm's product pipeline includes Sotatercept, ACE-1334 and REBLOZYL (luspatercept-aamt). Its lead pulmonary program, Sotatercept, is an activin receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC).
Company Info
Acceleron Pharma
128 Sidney St
Cambridge MASSACHUSETTS 02139
P: 16176499200.0
CEO: Habib J. Dable
Employees: 312
Website: http://www.acceleronpharma.com/
XLRN News
a year ago - InvestorPlace3 Dow Stocks to Take Seriously in 2023The top Dow stocks for 2023 are all big free cash flow generators that ought to be able to cope with whatever next year brings.
2 years ago - Market News VideoNotable Wednesday Option Activity: XLRN, LOW, ZGNX
2 years ago - Avoro Capital AdvisorsAvoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer
2 years ago - InvestorPlaceMerck Is a Dividend Play Ready to Get Back in GearPfizer has been beating MRK stock in 2021, but that relative performance may reverse next year, with new drugs and acquisitions ahead.
3 years ago - The Motley FoolIs Merck's Planned Acquisition of Acceleron in Trouble?There's nothing to worry about with a recent delay.
3 years ago - Avoro Capital AdvisorsAvoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate OfferXLRN Twits
Here you can normally see the latest stock twits on XLRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
